Karyopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of Directors; Dr. Sharon Shacham Named President of Research

Karyopharm Therapeutics Announces Ken Weg & Barry Greene Join Board of
Directors; Dr. Sharon Shacham Named President of Research & Development

NATICK, Mass., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.,
a leader in the new field of nuclear transport modulators, announces that Ken
Weg and Barry Greene have joined its Board of Directors. In addition, Founder
and Chief Scientific Officer (CSO) Sharon Shacham, PhD, MBA, is named to the
newly created position of President, Research & Development, as the Company
prepares for the next phase of development of its novel oral selective
inhibitors of nuclear export (SINEs) KPT-330 for human cancers and KPT-335 for
canine lymphomas.

Ken Weg has over 33 years of pharmaceutical industry experience with Merck and
Bristol-Myers Squibb (BMS) and will provide critical guidance in the areas of
strategic planning, corporate and business development, product development,
and commercial operations. Prior to his retirement, he was President,
Worldwide Medicines Group, BMS, responsible for all ethical pharmaceuticals
and over-the-counter medicines on a global basis. Mr. Weg was elected to the
Board of Directors of BMS in May 1995 and as Vice Chairman in May 1999. He
retired in February 2001 to become Founder and the Chairman of Clearview
Projects, a strategic advisory group to the pharmaceutical, biotechnology and
life science industries. Mr. Weg served on the Board of Directors of Fox Chase
Cancer Center, and is currently a co-founder and director of Metamark Genetics
and AVEO Pharmaceuticals, Inc. He was the non-executive Chairman of Millennium
Pharmaceuticals, Inc. until the company was acquired by Takeda in 2008.In
referring to Karyopharm, Mr. Weg commented, "It is rare to see a company
create an entirely new class of drugs for the treatment of cancer and related
diseases.We have a great many options ahead of us, and I am extremely pleased
to be a part of such an exciting and novel endeavor."

Barry Greene is the President and Chief Operating Officer of Alnylam
Pharmaceuticals Inc. (Nasdaq:ALNY), and brings over 20 years of strategic
business and commercialization experience in healthcare, pharmaceutical, and
biotechnology industries. Prior to Alnylam, Mr. Greene was General Manager of
Oncology at Millennium Pharmaceuticals, Inc., where he led the company's
global strategy and execution for its oncology business including strategic
business direction and execution, culminating in the successful approval and
launch of VELCADEĀ® (bortezomib) in mid 2003. He was also Vice President of
Marketing and Customer Services for AstraZeneca formerly AstraMerck; Vice
President Strategic Integration with responsibility for the AstraZeneca North
America post-merger integration.Mr. Greene commented, "I am very excited
about joining the Board of Karyopharm, where I see a great deal of potential
for a completely novel approach to the treatment of multiple cancers.The
Karyopharm team has brought their own proprietary compounds from concept to
clinic in an expeditious fashion, and I am looking forward to helping them
move these exciting agents forward."

Sharon Shacham, PhD, MBA, Karyopharm's Founder and CSO, originally conceived
of the novel SINEs for the treatment of cancer, inflammatory disorders, and
other diseases.She has overseen all aspects of the discovery and development
of the SINE compounds and has been appointed President of Research and
Development. Dr. Shacham was formerly Senior Vice President of Drug Discovery
at Epix Pharmaceuticals (EPIX), and her PhD thesis work on structure-based
drug design of GPCRs formed the basis for the creation of Predix
Pharmaceuticals, which later merged with EPIX.Dr. Shacham holds a PhD in
biophysical chemistry / computational biophysics and an MBA from Tel Aviv
University.She holds over 20 patents and has discovered multiple drugs that
are in clinical trials.

Michael Kauffman, MD, PhD, Karyopharm's Chief Executive Officer, will also
assume the role of Chief Medical Officer.Kauffman remarked, "As we plan our
Phase 2/3 development of KPT-330, we are particularly excited about Ken and
Barry joining the Board of Directors, and Sharon assuming broader leadership
responsibilities. The breadth and experience of our team, which also includes
Dr. Mansoor Raza, Chief Oncologist at Copenhagen's University Hospital, and
Dr. Giulio Draetta, co-founder, chairman of Karyopharm's Scientific Advisory
Board and Director of the Institute for Applied Cancer Science, MD Anderson
Cancer Center, position us to plan and execute on the next phase in the
development of SINEs for patients with different types of cancers.We look
forward to adding these promising new agents forward in the fight against
neoplastic and other diseases."

About Karyopharm

Karyopharm Therapeutics Inc. was founded by Drs. Sharon Shacham and Michael
Kauffman in 2009 and has emerged as a leader in the new field of nuclear
transport modulators.The company's selective inhibitors of nuclear export
(SINE) function by trapping multiple tumor suppressor proteins in the nucleus,
resulting in anti-cancer activity across multiple tumor types. In
collaboration with many academic laboratories, SINEs, targeting the major
nuclear exporter CRM1, exert robust anti-cancer activity in diverse
preclinical models of cancer. The lead SINE KPT-330 is now in Phase 1 clinical
studies for advanced solid tumor and hematologic malignancies. The related
SINE KPT-335 is being evaluated as an oral treatment for dogs with
Non-Hodgkin's Lymphoma, one of the most common canine cancers.The Company is
also testing SINEs in autoimmune, viral and dermatologic disorders. Karyopharm
Therapeutics is located in Natick, Massachusetts.

CONTACT: Dr. Michael Kauffman
         mkauffman@karyopharm.com
 
Press spacebar to pause and continue. Press esc to stop.